Day: October 21, 2023

MILA 300929 – Bondholders meeting 20 October 2023 In accordance with the provisions of the bond MILA 300929 (the “Bond”), Sunstone IV hf. (the “Issuer”) now calls for a Bondholders Meeting, to be held at the Issuer’s office at Stórhöfði 22-30, 110 Reykjavík, Iceland at 13:00 on 6 November 2023. The Bondholders Meeting’s agenda:Proposal to change the Article of the Bond relating to payments of principal and interest, for the purpose of correcting a drafting error in the Bond.Attached to this meeting notification are the Issuer’s proposals. In accordance with the provisions of the Bond, the Bond can be amended by a Bondholders Meeting, which shall be called with no less than two-week notice. Bondholders Meetings can conclude all matters within the agenda if the meeting is called in accordance with the provisions of the Bond. The voting...

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses32% (6/19) confirmed response rate in patients with small cell lung cancer (SCLC), including one confirmed complete response 42% (5/12) confirmed response rate in other neuroendocrine tumor types, including two confirmed complete responsesGenerally well tolerated; cytokine release syndrome (CRS) most common, predominantly low-grade, with no Gr3 CRS in 1 mg priming dose cohorts Enrollment in monotherapy dose cohorts nearing completion, on track to select Phase 2 dose(s) by end of 2023 Results will be presented in a poster session at ESMO Congress 2023 on Monday, October 23, 2023 and management will hold a webcast at 8:00 a.m. ET / 2:00 p.m. CEST to review the data, following...

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of patients who experienced a pathologic complete response in the primary analysis TARRYTOWN, N.Y., Oct. 21, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The results from an international Phase 2 trial were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 and concurrently published in The Lancet Oncology. “Advanced, resectable cutaneous...

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 21 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announces that the three-year overall survival (OS) data from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has...

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion regression Favorable safety profile with mainly Grade 1 and 2 treatment related adverse events; MTD not reached and dose escalation remains ongoing Company...

VANCOUVER, British Columbia, Oct. 20, 2023 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company“) is pleased to announce, further to its news releases on April 28, 2023, June 23, 2023, July 21, 2023, and September 1st, 2023, that it has further extended its engagement of Financial Star News Inc. (“FSN”) (address: 701 West Georgia Street, Suite 1500, Vancouver, British Columbia V7Y 1C6; email: info@thefinancialstar.com) for marketing services for up to an additional 45 days commencing on October 23rd, 2023, provided that the term of the marketing services may be extended or shortened at the discretion of management depending on, amongst other things, the efficiency of the marketing services. As previously disclosed, FSN has and shall continue to, as appropriate, create...